D. Nosov

Иммуноопосредованные нежелательные явления

А. В. Новик, М. Ф. Баллюзек, Д. А. Васильев, Н. В. Жукова et autres

.

kr (code pays fourni par la source)

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma

Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et autres

de, us, ru, gb, ca, cz, ua, br, fr, ie, jp (code pays fourni par la source)

Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).

Bernard Escudier, Robert J. Motzer, Thomas Powles, Nizar M. Tannir et autres

499 Background: Cabozantinib (C) inhibits tyrosine kinases including VEGFRs, MET, and AXL. The METEOR phase 3 trial (NCT01865747) met its primary endpoint of significant improvement in PFS with C versus everolimus (E) in pts with advanced clear cell RCC and prior exposure …

fr, us, gb, au, dk, de, ca, cz, ru, cl, it, pl, be (code pays fourni par la source)

Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).

Thomas E. Hutson, D. Nosov, Piotr Tomczak, Igor Bondarenko et autres

4557 Background: An extension and open access study allowed follow up of patients (pts) from TIVO-1 (301), an open label, phase III multinational trial in which pts with metastatic renal cell carcinoma (mRCC) were randomized to either tivozanib or sorafenib (both VEGF …

us, ru, pl, ua, it, gb (code pays fourni par la source)

Гастроинтестинальные стромальные опухоли желудка у детей

A.B. Ryabov, М П Никулин, О. А. Анурова, О П Близнюков et autres

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

Robert J. Motzer, D. Nosov, Tim Eisen, Oleg Lipatov et autres

Tivozanib Pharmacokinetic (PK)/Pharmacodynamic (PD) Analysis of Blood Pressure (BP) and Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2) in Patients with Advanced Renal Cell Carcinoma (RCC)

D. Nosov, Robert J. Motzer, John W. Loewy, Lucy S. Hodge et autres

ru, us (code pays fourni par la source)

Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC).

D. Nosov, Pankaj Bhargava, W. B. Esteves, Andrew Strahs et autres

4550 Background: Tivozanib is a potent and selective small molecule tyrosine kinase inhibitor (TKI) of VEGFR-1, -2, and -3. Methods: Patients (pts) with advanced RCC (all histologies) and no prior VEGF-targeted therapy were enrolled. All pts received 16 wks of open-label tivozanib …

Activity of tivozanib (AV-951) in patients (Pts) with different histologic subtypes of renal cell carcinoma (RCC).

Pankaj Bhargava, B. Esteves, Mohammed Al-Adhami, D. Nosov et autres

327 Background: This phase 2 randomized discontinuation trial evaluated tivozanib, a potent and selective vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 kinase inhibitor. Median progression-free survival (PFS) in all pts was 11.8 mo, and the objective response rate (ORR) was …

in, us (code pays fourni par la source)

Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

Pankaj Bhargava, B. Esteves, Mohammed Al-Adhami, D. Nosov et autres

4599 Background: Tivozanib, a potent and selective inhibitor of VEGFR-1, 2, and 3 kinases, was tested in a phase II RDT that included patients (pts) with all histologies of RCC, as well as pts who had not undergone nephrectomy or had received …

Клинические испытания аутологичной вакцины на основе опухолевых клеток, модифицированных геном tag-7

И. Н. Михайлова, Lev Demidov, А. Ю. Барышников, О. С. Бурова et autres

Vaccinotherapy with gene-modified tumor cells was shown to be a promising treatment method for malignant tumors. The treatment method using autologous tumor cells transferred by tag-7 gene was developed. Pre-clinical investigations demonstrated specificity in vitro and in vivo and low toxicity of …

841 Prognostic factors in advanced nonseminomatous germ cell tumors (NSGCT): Importance of primary tumor (PT) histology and numbers of negative prognostic factors (NPF)

A. Tryakin, Sergei Tjulandin, Olga Scherbakova, D. Nosov et autres